AMPLITUDE Trial Examines PARP Inhibition in HRR Gene–Mutated mCSPC
October 4th 2021Although the efficacy of PARP inhibitors has been established in patients with metastatic castration-resistant prostate cancer in previous studies, the use of these agents earlier on in the disease process has yet to be evaluated.
Read More
Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.
Read More
Frontline Pembrolizumab/Chemo Represents New Standard in Metastatic TNBC With PD-L1 CPS ≥10
September 28th 2021Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.
Read More
Acalabrutinib Continues to Showcase Impressive Activity in Relapsed/Refractory MCL
September 21st 2021Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.
Read More
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer
September 14th 2021Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
Read More
PARP Inhibitors Play Key Role in Prostate Cancer Paradigm, as Hunt for Biomarkers Continues
August 31st 2021Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents
Read More
Fixed-Duration Ibrutinib/Venetoclax Provides Deep, Durable Responses in Frontline CLL/SLL
August 10th 2021A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).
Read More
Rusfertide Could Represent New Therapeutic Option in Polycythemia Vera
August 6th 2021Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.
Read More
Rini Remarks on Remaining Questions With Pembrolizumab/Axitinib in Frontline Advanced Clear Cell RCC
August 4th 2021At a median follow-up of 42.8 months, frontline pembrolizumab plus axitinib continued to yield improved outcomes over sunitinib in patients with advanced clear cell renal cell carcinoma.
Read More
KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer
July 28th 2021Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.
Read More
Adavosertib, With or Without Olaparib, Showed Promising Efficacy in PARP-Resistant Ovarian Cancer
July 20th 2021Shannon Westin, MD, MPH, discusses the key takeaways from the EFFORT trial, future research directions with adavosertib, and the characteristics of PARP inhibitor resistance in patients with ovarian cancer.
Read More
Regorafenib/Nivolumab Elicits Better Responses in pMMR/MSS CRC Without Liver Metastases
July 14th 2021Marwan Fakih, MD, discusses the efficacy of regorafenib plus nivolumab in patients with pMMR/MSS CRC, the potential for VEGFR/PD-1 inhibitor combination regimens in this population, and future directions for research.
Read More
Tucatinib Detectable in CSF of HER2+ Metastatic Breast Cancer With Leptomeningeal Disease
July 12th 2021Tucatinib and ONT-993 were found to be detectable in the cerebrospinal fluid of all patients with leptomeningeal metastases from HER2-positive metastatic breast cancer who received treatment with tucatinib plus trastuzumab and capecitabine.
Read More